\
&
Contact us
\
&
Contact us
This was 7 months ago
LocationOnline
ProgrammesThe Health and Digital Executive Agency (HaDEA) of the European Commission is organising a virtual info session on the call DIGITAL-2025-BESTUSE-08: Accelerating the Best Use of Technologies, launched under the Digital Europe Work Programme 2025-2027. Participants will have the opportunity to learn all about the calls, the application process, and join Q&A sessions.
The Info session will cover the following two topics:
DIGITAL-2025-BESTUSE-08-NETWORKSICs: Network of Safer Internet Centres (SICs)
The objective of the topic is to continue to support national Safer Internet Centres (SICs), to provide online safety information, educational resources, public awareness tools and counselling and reporting services through dedicated helplines and hotlines for young people, teachers/educators, and parents/carers. Budget: € 42 million
DIGITAL-2025-BESTUSE-08-FACTCHECKERS: European Network of Factcheckers
The objective of the topic is to support the growth of a European Network of Factcheckers, which will deepen the language coverage and operational capacity of factchecking in Europe. Budget: € 5 million
More information on the event and the link to the session can be found on the event website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
